ArticleClinical & experimental metastasis1998
Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.
Article in Clinical & experimental metastasis, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 139 citations in OpenAlex.
- CMT-308, a Nonantimicrobial Chemically-Modified Tetracycline, Exhibits Anti-Melanogenic Activity by Suppression of Melanosome Export.Biomedicines · 2020Article
- Periodontal therapeutics: Current host-modulation agents and future directions.Periodontology 2000 · 2020Review
- Doxycycline attenuates cisplatin-induced acute kidney injury through pleiotropic effects.American journal of physiology. Renal physiology · 2018Article
- Mitochondria as oncotarget: a comparison between the tetracycline analogs doxycycline and COL-3.Oncotarget · 2018Article
- Cathepsin K-targeted sub-micron particles for regenerative repair of vascular elastic matrix.Acta biomaterialia · 2017Article
- Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.Journal of cellular and molecular medicine · 2015Article
- Emergence of a metalloproteinase / phospholipase A2 axis of systemic inflammation.Metalloproteinases in medicine · 2015Article
- Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers.Clinical & experimental metastasis · 2015Article
- Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cells.PloS one · 2014Article
- Multifunctional nanoparticles for doxycycline delivery towards localized elastic matrix stabilization and regenerative repair.Acta biomaterialia · 2013Article
- Overexpression of integrin-linked kinase promotes lung cancer cell migration and invasion via NF-κB-mediated upregulation of matrix metalloproteinase-9.International journal of medical sciences · 2013Article
- Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma.TheScientificWorldJournal · 2013Review
- Therapeutic application of natural inhibitors against snake venom phospholipase A(2).Bioinformation · 2012Article
- Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers.Pharmacological research · 2011Review
- Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria.Cancer cell international · 2010Article
- Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells.British journal of pharmacology · 2010Article
- Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?World journal of surgical oncology · 2009Article
- Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration.Neurochemistry international · 2007Article
- Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices.The American journal of pathology · 2006Article
- Stress hormone-mediated invasion of ovarian cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Recent work has shown that chemically modified tetracyclines (CMTs) are potent inhibitors of matrix metalloproteinase (MMP) activity, both in vitro and in vivo, which is distinct from their antimicrobial activities (Golub et al. Crit Rev Oral Biol Med, 2, 297-321, 1991; Ryan et al. Curr Opin Rheumatol, 8, 23847, 1996). The process of tumor cell invasion requires MMP-mediated degradation of extracellular matrix barriers as a key step in the metastasic cascade. In this study, we examined the effect(s) of doxycycline and CMTs on extracellular levels of gelatinase A and B activity from a highly invasive and metastatic human melanoma cell line C8161, and correlated these observations with changes in the cells' biological behavior in an in vitro invasion assay and in an in vivo SCID mouse model. The results indicate that coincident with the ability of these compounds to differentially suppress extracellular levels of gelatinase activity, C8161 cells treated with doxycycline, CMT-1, CMT-3, or CMT-6 were less invasive in vitro in a dose-dependent manner (3-50 microg/ml). Furthermore, data derived from the in vivo model indicate that SCID mice dosed orally with CMT-1 or CMT-3 contained a reduced number of lung metastases following i.v. injection of C8161 cells via tail vein inoculation. These observations suggest that careful screening of different CMTs could lead to the identification of compounds which suppress the formation and magnitude of metastases associated with certain cancers, and if used as an adjunct to other treatment regimes, lead to greater efficacy in the treatment of metastatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.